Search Results

There are 3981 results for: content related to: Patient satisfaction with the benefits of overactive bladder treatment: Exploration of influencing factors and development of a satisfaction assessment instrument

  1. Abstract

    Neurourology and Urodynamics

    Volume 35, Issue S1, February 2016, Pages: S6–S109,

    Version of Record online : 1 FEB 2016, DOI: 10.1002/nau.22967

  2. You have free access to this content
    Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study

    BJU International

    Volume 107, Issue 4, February 2011, Pages: 603–611, Jean-Jacques Wyndaele, Evan R. Goldfischer, Jon D. Morrow, Jason Gong, Li-Jung Tseng and Myung-Soo Choo

    Version of Record online : 22 SEP 2010, DOI: 10.1111/j.1464-410X.2010.09587.x

  3. You have free access to this content
    Outcome Measurement of Overactive Bladder

    LUTS: Lower Urinary Tract Symptoms

    Volume 4, Issue s1, March 2012, Pages: 62–66, Chi-Shun LIEN and Eric Chieh-Lung Chou

    Version of Record online : 19 MAR 2012, DOI: 10.1111/j.1757-5672.2011.00126.x

  4. You have free access to this content
    Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial

    BJU International

    Volume 114, Issue 3, September 2014, Pages: 418–426, Christopher Chapple, Tim Schneider, François Haab, Franklin Sun, Laurence Whelan, David Scholfield, Erika Dragon and Erin Mangan

    Version of Record online : 1 JUL 2014, DOI: 10.1111/bju.12678

  5. The psychometric validation of the OAB family impact measure (OAB-FIM)

    Neurourology and Urodynamics

    Volume 29, Issue 3, March 2010, Pages: 359–369, Karin S. Coyne, Louis S. Matza, Jessica Brewster-Jordan, Christine Thompson and Tamara Bavendam

    Version of Record online : 9 MAR 2009, DOI: 10.1002/nau.20715

  6. You have free access to this content
    Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study

    International Journal of Clinical Practice

    Volume 65, Issue 2, February 2011, Pages: 211–218, R. D. Crosby, S. D. Mathias and T. S. Marshall

    Version of Record online : 16 JAN 2011, DOI: 10.1111/j.1742-1241.2010.02532.x

  7. You have free access to this content
    Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting

    BJU International

    Volume 109, Issue 4, February 2012, Pages: 572–580, Carl V. Asche, Jaewhan Kim, Amit S. Kulkarni, Paula Chakravarti and Karl-Erik Andersson

    Version of Record online : 20 JUL 2011, DOI: 10.1111/j.1464-410X.2011.10436.x

  8. You have full text access to this OnlineOpen article
    Patient-reported outcomes with the β3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder

    Neurourology and Urodynamics

    Vik Khullar, Gerard Amarenco, Javier C. Angulo, Mary Beth Blauwet, Jameel Nazir, Isaac A. Odeyemi and Zalmai Hakimi

    Version of Record online : 19 AUG 2015, DOI: 10.1002/nau.22844

  9. You have full text access to this OnlineOpen article
    Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

    International Journal of Clinical Practice

    Volume 62, Issue 11, November 2008, Pages: 1664–1674, N. Zinner, K. C. Kobashi, U. Ebinger, A. Viegas, M. Egermark, E. Quebe-Fehling and P. Koochaki

    Version of Record online : 22 SEP 2008, DOI: 10.1111/j.1742-1241.2008.01893.x

  10. Linguistic validation of the N-QOL (ICIQ), OAB-q (ICIQ), PPBC, OAB-S and ICIQ-MLUTSsex questionnaires in 16 languages

    International Journal of Clinical Practice

    Volume 64, Issue 12, November 2010, Pages: 1643–1652, S. McKown, L. Abraham, K. Coyne, M. Gawlicki, E. Piault and V. Vats

    Version of Record online : 16 AUG 2010, DOI: 10.1111/j.1742-1241.2010.02489.x

  11. You have full text access to this OnlineOpen article
    Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder

    International Journal of Clinical Practice

    Volume 70, Issue 1, January 2016, Pages: 66–81, L. K. Lee, A. Goren, K. H. Zou, K. Odell, D. Russell, A. L. Araiza and X. Luo

    Version of Record online : 9 DEC 2015, DOI: 10.1111/ijcp.12758

  12. You have free access to this content
    Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial

    BJU International

    Volume 107, Issue 9, May 2011, Pages: 1432–1440, Steven A. Kaplan, Tim Schneider, Jenelle E. Foote, Zhonghong Guan, Martin Carlsson and Jason Gong

    Version of Record online : 21 SEP 2010, DOI: 10.1111/j.1464-410X.2010.09640.x

  13. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder

    LUTS: Lower Urinary Tract Symptoms

    Chung-Cheng WANG, Yuan-Hong JIANG and Hann-Chorng KUO

    Version of Record online : 2 JUL 2015, DOI: 10.1111/luts.12103

  14. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine

    International Journal of Clinical Practice

    Volume 62, Issue 6, June 2008, Pages: 925–931, K. S. Coyne, V. Elinoff, D. A. Gordon, D. Y. Deng, M. Brodsky, D. B. Glasser, Z. Jumadilova and M. Carlsson

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1742-1241.2008.01778.x

  15. You have free access to this content
    Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome

    LUTS: Lower Urinary Tract Symptoms

    Volume 4, Issue s1, March 2012, Pages: 32–41, Hann-Chorng KUO

    Version of Record online : 19 MAR 2012, DOI: 10.1111/j.1757-5672.2011.00131.x

  16. You have free access to this content
    Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

    Neurourology and Urodynamics

    Volume 33, Issue 1, January 2014, Pages: 17–30, Christopher R. Chapple, Linda Cardozo, Victor W. Nitti, Emad Siddiqui and Martin C. Michel

    Version of Record online : 11 OCT 2013, DOI: 10.1002/nau.22505

  17. Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms

    International Journal of Clinical Practice

    Volume 66, Issue 7, July 2012, Pages: 663–670, K.-S. Lee, Y.-S. Lee, J. C. Kim, J. T. Seo, J. Z. Lee and M.-S. Choo

    Version of Record online : 15 JUN 2012, DOI: 10.1111/j.1742-1241.2012.02951.x

  18. You have free access to this content
    The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS

    BJU International

    Volume 108, Issue 9, November 2011, Pages: 1459–1471, Karin S. Coyne, Chris C. Sexton, Zoe S. Kopp, Caty Ebel-Bitoun, Ian Milsom and Chris Chapple

    Version of Record online : 3 MAR 2011, DOI: 10.1111/j.1464-410X.2010.10013.x

  19. You have free access to this content
    Symptom severity and patient perceptions in overactive bladder: how are they related?

    BJU International

    Volume 104, Issue 7, October 2009, Pages: 968–972, Yukio Homma and Momokazu Gotoh

    Version of Record online : 11 MAR 2009, DOI: 10.1111/j.1464-410X.2009.08498.x

  20. An overactive bladder symptom and health-related quality of life short-form: Validation of the OAB-q SF

    Neurourology and Urodynamics

    Volume 34, Issue 3, March 2015, Pages: 255–263, Karin S. Coyne, Christine L. Thompson, Jin-Shei Lai and Chris C. Sexton

    Version of Record online : 13 JAN 2014, DOI: 10.1002/nau.22559